Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Administering initial chemotherapy debulking before introducing bispecific antibodies drastically reduces the incidence of cytokine release syndrome in upfront diffuse large B-cell lymphoma. In a phase 2 trial combining glofitumab with R-CHOP, delaying glofitumab initiation until cycle 3 achieved substantial tumor debulking first. Consequently, cytokine release syndrome dropped to 10% while achieving a 90% complete response rate and 95% MRD negativity at 12 months.

Related Insights

Prophylactically administering tocilizumab before bispecific antibody treatment can slash the incidence of cytokine release syndrome (CRS) from ~75% down to 20%. This simple intervention, analogous to using G-CSF for neutropenia, mitigates side effects and makes outpatient administration a much safer and more feasible option for patients.

The LOTUS-7 trial (loncastuximab + glofitimab) illustrates a key principle for using bispecific antibodies safely: combining them with another active, tumor-debulking drug mitigates Cytokine Release Syndrome (CRS). The speaker identifies this as a "thematic" finding, where reducing tumor bulk directly lowers the risk of this major toxicity, making potent combinations more tolerable.

Administering tocilizumab before the first bispecific antibody dose significantly reduces Cytokine Release Syndrome (CRS) risk. This proactive strategy enables safer outpatient treatment, lowering hospital admissions and improving patient access, especially in community settings.

Oncologists hypothesize that using the T-cell engager Tarlatumab after chemotherapy has reduced tumor volume may be a safer strategy. Real-world evidence suggests high tumor burden increases the risk of severe Cytokine Release Syndrome (CRS), so using chemotherapy to first cytoreduce the cancer could mitigate this toxicity.

Combining the ADC Loncastuximab before a bispecific antibody may lower the bispecific's toxicity, potentially through a debulking effect. This surprising finding suggests a strategy to improve the tolerability and delivery of bispecifics, especially in community settings.

To mitigate the risk of severe Cytokine Release Syndrome (CRS) from bispecific antibodies in patients with high tumor burden, a debulking strategy is effective. Administering two initial cycles of chemotherapy dramatically reduces disease volume, leading to almost zero CRS when the bispecific is introduced, making the treatment much safer.

For DLBCL patients awaiting CAR-T cell therapy, particularly those with aggressive disease, bispecific antibodies are the preferred bridging strategy. This approach effectively controls disease and reduces tumor burden for better CAR-T outcomes, while avoiding the T-cell depleting effects of traditional chemotherapy.

The IntentiMig trial showed that proactively administering tocilizumab with a bispecific antibody resulted in a zero percent incidence of cytokine release syndrome (CRS). This safety improvement could be pivotal for the broader adoption of bispecifics in community oncology settings, which are less equipped to manage severe side effects.

An expert treating DLBCL states they no longer use bispecific antibodies as monotherapy. Combining them with partners like chemotherapy (GemOx) or ADCs (Polatuzumab) raises the complete response rate by 15-20%, offering a better chance of benefit for patients.

Giving prophylactic tocilizumab before bispecific antibody administration is a highly effective strategy to mitigate Cytokine Release Syndrome (CRS). This approach can reduce CRS rates from ~70% to 5-14%, making outpatient step-up dosing a much more feasible and safer option for community oncology centers.